The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11068 malaria professionals are enjoying the free benefits of MalariaWorld today

atovaquone-proguanil

Not Open Access | Unanticipated CNS Safety Signal in a Placebo-controlled, Randomized Trial of Co-administered Atovaquone-Proguanil and Amodiaquine

September 1, 2021 - 15:48 -- NOT Open Access
Author(s): 
Chalon S, Chughlay MF, Abla N, Tchouatieu AM, Haouala A, Hutter B, Lorch U, Macintyre F
Reference: 
Clin Pharmacol Ther. 2021 Aug 28

Atovaquone-proguanil (ATV-PG) plus amodiaquine (AQ) has been considered as a potential replacement for sulfadoxine-pyrimethamine plus AQ for seasonal malaria chemoprevention (SMC) in African children. This randomized, double-blind, placebo-controlled, parallel group study assessed the safety, tolerability, and pharmacokinetics (PK) of ATV-PG plus AQ in healthy adult males and females of Black sub-Saharan African origin.

Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria

January 20, 2021 - 07:33 -- Open Access
Author(s): 
Blanshard A, Hine P
Reference: 
Cochrane Database Syst Rev. 2021 Jan 15;1:CD004529

The World Health Organization (WHO) in 2015 stated atovaquone‐proguanil can be used in travellers, and is an option in malaria‐endemic areas in combination with artesunate, as an alternative treatment where first‐line artemisinin‐based combination therapy (ACT) is not available or effective. This review is an update of a Cochrane Review undertaken in 2005.

Not Open Access | Selection of cytochrome b mutants is rare among Plasmodium falciparum patients failing treatment with atovaquone-proguanil in Cambodia

December 29, 2020 - 14:56 -- NOT Open Access
Author(s): 
Lin JT, Waltmann A, Wojnarski M, et al.
Reference: 
Antimicrob Agents Chemother. 2020 Dec 23:AAC.01249-20

Atovaquone-proguanil remains effective against multidrug-resistant Plasmodium falciparum in Southeast Asia, but resistance is mediated by a single point mutation in cytochrome b (cytb) that can arise during treatment. Among 14 atovaquone-proguanil treatment failures in a clinical trial in Cambodia, only one recrudescence harbored the cytb mutation Y268C.

NOT Open Access | HRP2/3 Mutation in Recrudescent Plasmodium falciparum Malaria Case Acquired in Ethiopia

October 21, 2020 - 08:17 -- NOT Open Access
Author(s): 
Gefen-Halevi S, Belinson V, Manor U, Gazit Z, Smollan G, Belausov N, Biber A, Schwartz E, Grossman T, Leshem E, Amit S
Reference: 
J Travel Med. 2020 Oct 15:taaa196

A 65-year-old Israeli working in Welkait, Ethiopia, not using malaria prophylaxis, developed fever. Malaria RDT was consistent with non-falciparum malaria (plasmodium LDH+/HRP-) but microscopy showed typical P. falciparum.

NOT Open Access | Atovaquone-Proguanil treatment failure in a case of pediatric Plasmodium falciparum infection: malabsorption and resistance

August 11, 2020 - 14:05 -- NOT Open Access
Author(s): 
L'Huillier AG, Lau R, Bitnun A, Boggild AK
Reference: 
Travel Med Infect Dis. 2020 Aug 4:101829

No abstract available

Subscribe to RSS - atovaquone-proguanil